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http://dx.doi.org/10.1016/j.jacl.2015.03BACKGROUND: Once-daily, oral ETC-1002 reduces low-density lipoprotein cholesterol (LDL-C)
and has beneficial effects on other cardiometabolic risk factors but has not been examined in statin
intolerant patients.
OBJECTIVES: To study the efficacy and safety of ETC-1002 (a novel LDL-C–lowering agent) in
patients with hypercholesterolemia and a history of statin intolerance.
METHODS: Patients intolerant to at least 1 statin were entered into this multicenter, double-blind,
8-week trial. Participants were required to have a history of muscle complaints that developed during
statin treatment and resolved within 4 weeks of statin discontinuation. Patients (n 5 56) were random-
ized in a 2:1 ratio to ETC-1002 60 mg daily or placebo. The ETC-1002 dose was increased at 2-week
intervals to 120 mg, 180 mg, and 240 mg. The primary end point was the percentage change from base-
line to week 8 in calculated LDL-C.
RESULTS: ETC-1002 reduced LDL-C 28.7% more than placebo (95% confidence interval, 235.4
to 222.1; P , .0001). ETC-1002 significantly reduced non–high-density lipoprotein cholesterol, total
cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein. Triglycerides and high-density
lipoprotein cholesterol did not change with ETC-1002 treatment. Sixty-two percent of patients
receiving ETC-1002 and none in the placebo group achieved the 2004 National Cholesterol Education
Program Adult Treatment Panel III LDL-C goal (P , .0001). Muscle-related adverse events occurred
with similar frequency in the placebo and ETC-1002 treatment groups, causing no discontinuations in
ETC-1002–treated patients.
CONCLUSIONS: ETC-1002 appears to be effective at reducing LDL-C and was well tolerated in
patients with statin-associated muscle complaints. Longer and larger studies are required to confirm
the absence of muscle side effects.
 2015 National Lipid Association. This is an open access article under the CCBY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).of Cardiology, Hartford Hospital,
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Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A
reductase inhibitors, are among the most effective in-
terventions for reducing cardiovascular events.1 In contrast,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/
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worse cardiovascular outcomes.2 Statins can produce
muscle complaints ranging from myalgia to rare but life-
threatening rhabdomyolysis.3,4 A recent, large, observa-
tional survey reports that statin-associated muscle pain
affects 29% of statin users and causes 15% of these individ-
uals to stop statin therapy.3
Recent cholesterol management guidelines from the
American College of Cardiology and the American Heart
Association acknowledge the problem of statin intolerance
and offer recommendations for the management of statin-
associated muscle symptoms, including the use of other
lipid-regulating medications.1 These guidelines, however,
also note the paucity of data to guide treatment of statin
intolerant patients and cite the need for randomized clinical
trials in this population.1
ETC-1002 is a novel low-density lipoprotein cholesterol
(LDL-C)–lowering agent in development for the treatment
for dyslipidemia. The agent inhibits both sterol and fatty
acid synthesis and enhances fatty acid oxidation in pre-
clinical models and produces beneficial effects on proa-
therogenic lipids.5,6 These effects are linked to its dual
mechanism of action: inhibition of adenosine triphosphate
citrate lyase and activation of adenosine monophosphate–
activated protein kinase.6 Once-daily, oral ETC-1002 in
patients with hypercholesterolemia reduces LDL-C and im-
proves other cardiometabolic risk factors.7,8 The present
study evaluates the lipid-altering efficacy and safety of
8 weeks of ETC-1002 treatment in patients with hypercho-
lesterolemia and a history of statin intolerance.Methods
Study design
This was a phase 2, multicenter, randomized,
double-blind, placebo-controlled, parallel-group trial
(NCT01751984) conducted at 5 sites in the United States.
The trial included a screening phase (weeks 24 to 0)
with single-blind placebo run-in (weeks 22 to 0) and an
8-week double-blind treatment phase (weeks 0–8; Fig. 1).
During screening, eligible patients underwent a washout
of any lipid-regulating drugs and supplements for at least
4 weeks. During the 2-week placebo run-in, patients report-
ing muscle-related or other clinically significant adverseFigure 1 Study desigevents (AEs) were excluded. After screening, eligible
patients were randomized in a 2:1 ratio to receive either
oral ETC-1002 or placebo daily for 8 weeks. Patients in
the ETC-1002 group initially received 60 mg daily for
2 weeks. The ETC-1002 dose was increased at 2-week
intervals to 120, 180, and 240 mg daily. The escalating
dose schedule was designed to characterize the magnitude
of LDL-C reduction with increasing ETC-1002 dose and
to help select optimum doses for subsequent studies in pa-
tients with statin-associated muscle complaints. ETC-1002
was dispensed in white, opaque, size #3, gelatin capsules
containing either 20 mg of ETC-1002 with 100-mg micro-
crystalline cellulose (MCC) filler or 40 mg of ETC-1002
and 80-mg MCC filler. Placebo capsules were dispensed
as matching white, opaque, size #3, gelatin capsules con-
taining 120-mg MCC filler. All participants ingested 6 cap-
sules by mouth once daily; the number of capsules ingested
daily did not change for the duration of the study in either
treatment group. Study visits occurred at weeks 24, 23,
22, 0, 2, 4, 6, 7, and 8.
Informed consent was obtained from patients using
documents approved by the local and central institutional
review boards.
Study participants
Eligible patients were men and postmenopausal or
surgically sterile women aged 18 to 80 years with hyper-
cholesterolemia and a history of intolerance to $1 statins,
which was defined as the development of new myalgia,
muscle cramps, muscle aches, or muscle weakness during
statin treatment and resolution or marked improvement of
muscle symptoms within 4 weeks of statin cessation. In
those patients taking lipid-lowering therapy at screening
(visit, 1; week, 24), hypercholesterolemia was defined as a
fasting, calculated LDL-C between 100 and 220 mg/dL and
triglycerides ,350 mg/dL. In those patients not taking
lipid-lowering therapy at screening visit 1, hypercholester-
olemia was defined as an LDL-C between 115 and
270 mg/dL and triglycerides ,400 mg/dL. Patients were
required to have a body mass index between 18 and
40 kg/m2. Patients with controlled type II diabetes mellitus
were eligible to participate provided they were not taking
exclusionary medications metformin or thiazolidinediones,
which were excluded because appropriate drug interaction
and safety studies have not yet been completed.n. PBO, placebo.
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diabetes mellitus; a history of major cardiovascular events
within 12 mo; a systolic blood pressure $160 mm Hg or
diastolic blood pressure $100 mm Hg; a history of chronic
arthritis or arthralgia that could not be differentiated from
myalgia; uncontrolled hypothyroidism; liver dysfunction,
including elevations in alanine aminotransferase (ALT),
aspartate aminotransferase, or total bilirubin.1.5 times the
upper limit of normal (ULN), or a history of unexplained
elevation in ALT or aspartate aminotransferase .2 times
ULN; renal dysfunction, including a calculated creatinine
clearance ,60 mL/min at screening visit 1; or unexplained
creatine kinase (CK) elevations .3 times ULN.
Efficacy end points
The primary end point was the percent change from
baseline to week 8 in calculated LDL-C. Secondary end
points included the percent change in non–high-density
lipoprotein cholesterol (HDL-C), total cholesterol, HDL-C,
triglycerides, apolipoprotein (apo) B, apo A1, lipopro-
tein(a), free fatty acids, and high-sensitivity C-reactive
protein (hsCRP). Additional secondary end points were the
number of patients achieving their National Cholesterol
Education Program Adult Treatment Panel III (NCEP
ATP-III) 2004 goal for LDL-C and the percent change in
lipids from baseline to weeks 2, 4, 6, and 8 in the respective
completer populations for those weeks.
Laboratory methods
Blood samples for efficacy laboratory measures were
obtained after a $12-h fast. Clinical laboratory tests were
performed by Medpace, Inc (Cincinnati, OH).
Triglycerides and cholesterol were measured with enzy-
matic colorimetric tests using the Olympus AU2700 or
AU5400 Analyzer (Center Valley, PA), following Centers
for Disease Control and Prevention calibration and refer-
ence procedures. HDL-C was measured after dextran sulfate
precipitation of apo B–containing lipoproteins.9 The for-
mula by Friedewald et al10 was used to calculate LDL-C,
unless triglycerides were .400 mg/dL, in which case,
LDL-C was measured after preparative ultracentrifugation
(beta quantification).11 Apo A1, apo B, lipoprotein(a), and
hsCRP were measured by rate immunonephelometry
using the Dade Behring BNII nephelometer (Siemens
Healthcare Diagnostics, Deerfield, IL). Free fatty acids
were measured using an enzymatic photometry assay pur-
chased from Wako Chemicals USA, Inc, Richmond, VA,
adapted to a Randox Daytona (Crumlin, UK) instrument.
Homocysteine, a biomarker of interest, was measured on
an Olympus analyzer using an enzymatic photometry assay
purchased from Diazyme Laboratories, Poway, CA.
Safety end points
Safety and side effects were determined from reports
of treatment-emergent AEs (TEAEs), including muscle-related AEs, as well as laboratory test results, findings at
physical examination, vital sign measurements, electrocar-
diographic measurements, waist and ankle circumference
measurements, and body weight. Blood pressure was
measured twice (only the second value was used) in
patients seated quietly for at least 5 min. AEs were coded
using the Medical Dictionary for Regulatory Activities
version 15.1. TEAEs were defined as those events that
began or worsened in severity after the first dose of study
medication and for up to 30 days after the last dose of study
medication. The intensity of AEs was graded as ‘‘mild,’’
‘‘moderate,’’ or ‘‘severe’’ by the study investigator, and
the relation to study drug was judged by the investigator
as ‘‘not related,’’ ‘‘possible,’’ ‘‘probable,’’ or ‘‘definite.’’ A
post hoc analysis was performed of muscle-related AEs
commonly associated with statin intolerance. These were
defined as all AEs coded as preferred terms in the Muscu-
loskeletal and Connective Tissue Disorders organ class
excluding the AEs of arthralgia, back pain, bursitis, joint
stiffness, joint swelling, plantar fasciitis, or spinal osteoar-
thritis (as these AEs are not typically associated with statin
intolerance).
Statistical methods
Descriptive statistics were calculated for continuous
data, and the number and percentage of patients in each
category were provided for categorical data. Missing values
for efficacy end points at their primary time point for
analysis were imputed using the last-observation-carried-
forward procedure. Only on-treatment values were carried
forward. Statistical testing of efficacy end points was
2-sided, and 5% was used as the level of significance
with no adjustment for multiple end points. Safety end
points were not tested for statistical significance.
The modified intent-to-treat (mITT) population was used
for the efficacy analyses and consisted of randomized
patients who had a baseline assessment, received $1 dose
of study medication, and had $1 on-treatment measure-
ment (excluding assessments taken .2 days after a dose of
study medication). Baseline was defined as the value from
week 0. Completer populations for weeks 2, 4, 6, and 8
consisted of patients in the mITT population with an
assessment at the specified time point. Like the mITT
population, the composition of a completer population
could change depending on the parameter being analyzed.
The safety population consisted of all randomized patients
who received $1 dose of study medication.
Demographic and baseline clinical characteristics were
summarized by treatment group for the safety population.
Baseline comparability between treatment groups was
examined using a t test for continuous parameters (except
hsCRP, for which a Wilcoxon rank-sum test was used)
and a Fisher’s exact or Fisher-Freeman-Halton test for cat-
egorical parameters.
Analysis of covariance (ANCOVA) was used to compare
ETC-1002 with placebo for the percent change from
Figure 2 Patient disposition. Asterisk, based on low-density lipoprotein cholesterol (LDL-C). mITT, modified intent to treat.
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model included the effect of treatment and the baseline
value as a covariate. Least square (LS) means and standard
errors were provided for each treatment group, as well as
the difference in LS means, corresponding 2-sided 95%
confidence interval (CI), and P value for the treatment com-
parison. Because of skewed distributions of lipoprotein(a),
free fatty acids, and hsCRP values, nonparametric analyses
were performed for these parameters; P values were
obtained from the Cochran-Mantel-Haenszel test in rank
ANCOVA, and median values were reported. A nonpara-
metric analysis of triglycerides was performed as a post
hoc sensitivity analysis. Secondary analyses of the percent
change in lipid measures from baseline to weeks 2, 4, 6,
and 8 were performed with separate ANCOVA models
that used the procedure described previously in the
completer populations for each of those weeks.
Participants’ NCEPATP-III risk category and associated
LDL-C goals were calculated using LDL-C and HDL-C
values from week 0 and patients’ risk factors.12 The number
and percentage of patients achieving their LDL-C goal at
weeks 24, 0, and 8 were summarized by treatment group.
Percentages at week 8 were based on those patients whohad not achieved their LDL-C goal at week 0. The propor-
tion of patients meeting their LDL-C goal at week 8 was
compared between treatment groups using Fisher’s exact
test. Treatment estimates and differences in proportions
were presented with 2-sided 95% CIs constructed using
the Clopper-Pearson approximation to the exact binomial
proportion13 for individual estimates within treatment
groups and the normal approximation for the difference
between treatment groups.
The sample size of 36 patients in the ETC-1002 group
and 18 patients in the placebo group was expected to
provide more than 95% power to detect a difference of 20%
between the study groups in the percent change from
baseline to week 8 in LDL-C. This sample size estimate
was based on a 2-sided t test at the 5% level of significance
and assumed a common standard deviation of 15% and a
dropout rate of 10%. Sample size calculations were per-
formed using nQuery Advisor version 7.0 (Statistical Solu-
tions, Ltd, Cork, Ireland). All data analyses were generated
using SAS version 9.1.3 (SAS Institute, Cary, NC) software
under the Microsoft Windows XP operating system (Red-
mond, Washington). Statistical procedures were finalized
before study completion and unblinding.
Table 1 Baseline demographic and clinical characteristics
Parameter ETC-1002 (n 5 37) Placebo (n 5 19) P value
Age, y, mean 6 SD 64 6 5 60 6 8 .0542
Female, n (%) 17 (46) 11 (58) .5731
White, n (%) 35 (95) 19 (100) .5435
Body mass index, kg/m2, mean 6 SD 30 6 4 29 6 5 .8064
Hypertension, n (%) 21 (57) 10 (53) .7843
Tobacco use, n (%) .4844
Never 19 (51) 9 (47)
Former 17 (46) 8 (42)
Current 1 (3) 2 (11)
NCEP ATP-III Risk Category, n (%) .6179
Very high 4 (11) 2 (11)
High 4 (11) 1 (5)
Moderate 27 (73) 13 (68)
Low 2 (5) 3 (16)
Patients at NCEP ATP-III LDL-C goal, n (%) 1 (3) 1 (5) 1
Fasting lipid measures, mg/dL, mean 6 SD
LDL-C 176 6 37 185 6 33 .3680
Total cholesterol 263 6 45 276 6 43 .2847
HDL-C 51 6 14 58 6 18 .0943
Triglycerides 200 6 172 166 6 72 .4221
Median hsCRP, mg/L (Q1, Q3) 2.2 (1.1, 4.8) 1.6 (0.4, 4.0) .2002
History of statin intolerance, n (%)
Intolerant of $2 statins 37 (100) 18 (95) .3393
Muscle symptoms, n (%)*
Ache 30 (81) 16 (84) 1
Pain 26 (70) 13 (68) 1
Weakness 20 (54) 12 (63) .5779
Cramps 17 (46) 7 (37) .5779
Other 2 (5) 4 (21) .1652
Location of muscle symptoms (bilateral), n (%)*
Back 3 (8) 1 (5) 1
Calf 23 (62) 12 (63) 1
Foot 2 (5) 2 (11) .5981
Forearm 5 (14) 1 (5) .6522
Hand 2 (5) 1 (5) 1
Neck 2 (5) 2 (11) .5981
Shoulder 8 (22) 4 (21) 1
Thigh 23 (62) 12 (63) 1
Upper arm 11 (30) 6 (32) 1
Other 5 (14) 5 (26) .2813
Time to onset after statin initiation, n (%) .2514
Within 1 wk 15 (41) 6 (32)
2 wk 12 (32) 8 (42)
3 wk 6 (16) 1 (5)
4 wk 0 2 (11)
.1–6 mo 2 (5) 2 (11)
.6 mo 2 (5) 0
Time to resolution after statin discontinuation, n (%) .2009
1 wk 21 (57) 16 (84)
2 wk 10 (27) 3 (16)
3 wk 4 (11) 0
$4 wk 2 (5) 0
HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; NCEP ATP-III,
National Cholesterol Education Program Adult Treatment Panel III Risk Category; SD, standard deviation.
NCEP ATP-III was calculated using risk factors for coronary heart disease and LDL-C and HDL-C values at baseline; Q1, first (lower) quartile; Q3, third
(upper) quartile.
Baseline is defined as the value from week 0.
*Because participants could be counted in more than one category for these parameters, treatment groups were compared individually for each
category.
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Table 2 Percent change from baseline to week 8 in fasting lipid parameters and other biomarkers (mITT population)
Parameter
Mean (SE) LS mean (SE) change
from baseline (%)‡
Difference from
placebo, % (95% CI) P valueN Baseline (mg/dL)* End point (mg/dL)†
LDL-C
ETC-1002 35 176.4 (6.2) 119.0 (4.6) 232.0 (1.9) 228.7 (235.4, 222.1) ,.0001
Placebo 18 183.7 (7.8) 174.7 (6.7) 23.3 (2.7) — —
Non–HDL-C
ETC-1002 36 212.9 (6.7) 156.9 (5.3) 225.4 (2.0) 220.9 (228.0, 213.9) ,.0001
Placebo 18 216.7 (9.5) 204.6 (8.1) 24.4 (2.9) — —
Total cholesterol
ETC-1002 36 263.7 (7.5) 203.9 (5.6) 222.2 (1.6) 218.4 (224.2, 212.7) ,.0001
Placebo 18 275.4 (10.5) 260.3 (8.7) 23.7 (2.3) — —
HDL-C
ETC-1002 36 50.9 (2.4) 46.9 (2.7) 28.2 (2.5) 25.8 (214.5, 2.9) .1892
Placebo 18 58.7 (4.2) 55.7 (3.2) 22.4 (3.5) — —
Triglycerides
ETC-1002 36 201.9 (29.0) 202.6 (21.5) 11.2 (6.3) 18.7 (23.5, 40.8) .0962
Placebo 18 165.4 (17.5) 149.7 (14.8) 27.4 (9.0) — —
Apolipoprotein B
ETC-1002 29 127.3 (3.9) 102.1 (4.6) 219.7 (2.6) 215.3 (224.6, 26.0) .0019
Placebo 14 132.1 (6.0) 124.7 (5.6) 24.4 (3.8) — —
Apolipoprotein A1
ETC-1002 29 147.6 (4.1) 142.1 (4.5) 24.2 (2.0) 24.2 (211.7, 3.2) .2555
Placebo 14 164.5 (8.7) 160.2 (6.9) 0.1 (3.0) — —
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LS, least squares; mITT, modified intent to treat; SE, standard
error.
*Baseline is defined as the value from week 0.
†Missing values at week 8 end point were imputed using the last-observation-carried-forward procedure.
‡LS mean percent change from baseline to week 8 based on analysis of covariance model with effect of treatment and baseline value as a covariate.
Figure 3 Least squares (LS) mean percent change from baseline
to week 8 in calculated low-density lipoprotein cholesterol
(LDL-C) (primary end point). Asterisk, P , .0001 based on anal-
ysis of covariance model with effect of treatment and baseline
value as a covariate. CI, confidence interval.
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Patient disposition and characteristics
Of 106 patients assessed for eligibility, 50 were
excluded (Fig. 2). Of the 7 patients excluded during the pla-
cebo run-in phase, 1 patient was excluded for myalgia. A
total of 56 patients were randomized and treated. All 56
patients were included in the safety population; 3 patients
were not included in the mITT population. Five patients
(14%) treated with ETC-1002 and 3 patients (16%)
receiving placebo discontinued the study because of an AE.
At screening, before washout of lipid-lowering drugs
and randomization, 15 patients in total (11 of 37 patients in
the ETC-1002 group and 4 of 19 patients in the placebo
group) were taking a statin. At baseline, there were no
statistically significant differences in demographic and
clinical characteristics between the treatment groups
(Table 1). Most patients reported a history of intolerance
to 2 or more statins, with onset of associated muscle symp-
toms within 3 wk of statin initiation and general resolution
of muscle symptoms within 3 wk of statin discontinuation
(Table 1). Reported statin-associated muscle symptoms
were commonly muscle aches and muscle pains in the bilat-
eral calf and thigh.Efficacy end points
ETC-1002 reduced LDL-C from baseline to week 8
compared with placebo (P , .0001; Table 2; Fig. 3). Simi-
larly, ETC-1002 reduced LDL-C from baseline to weeks 2,
4, 6, and 8 in the completer populations for each time point,
Figure 4 Changes from baseline in low-density lipoprotein
cholesterol (LDL-C), non–high-density lipoprotein cholesterol
(HDL-C), and total cholesterol by treatment group. Analysis is
based on the completer population for each time point. Asterisk,
P # .0001 based on analysis of covariance model with effect of
treatment and baseline value as a covariate. PBO, placebo.
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1002–treated patients than placebo-treated patients at all
time points (P , .0001; Fig. 4). The reduction from base-
line in LDL-C with ETC-1002 was 18.0% greater at
week 2 than with placebo, and this difference increased
to 28.5% and 30.0% at weeks 4 to 8 (Fig. 4).
ETC-1002 decreased non–HDL-C, total cholesterol, and
apo B more than placebo (Table 2, Fig. 4), whereas the
changes in HDL-C, triglycerides, and apo A1 were no
different than placebo. ETC-1002 decreased hsCRP more
than placebo, but there were no differences from placebo
for lipoprotein(a) and free fatty acids (Table 3). Results
from the nonparametric post hoc sensitivity analysis of tri-
glycerides were supportive of those from the primary anal-
ysis: changes with ETC-1002 were no different than with
placebo (median percent change from baseline to week 8,Table 3 Nonparametric analysis of percent change from baseline to w
C-reactive protein (mITT population)
Parameter
Median (Q1, Q3)
N Baseline* End poin
Lipoprotein(a), mg/dL
ETC-1002 29 13.0 (6.0, 36.0) 13.0 (6.0
Placebo 14 12.0 (5.0, 26.0) 13.5 (4.0
Free fatty acids, mmol/L
ETC-1002 28 0.4 (0.3, 0.6) 0.4 (0.3
Placebo 14 0.4 (0.4, 0.5) 0.4 (0.3
hsCRP, mg/L
ETC-1002 28 1.7 (1.0, 4.3) 1.1 (0.8
Placebo 14 1.0 (0.3, 3.7) 1.1 (0.3
hsCRP, high-sensitivity C-reactive protein; mITT, modified intent to treat;
*Baseline is defined as the value from week 0.
†Missing values at week 8 end point were imputed using the last-observat
‡P values were obtained using the Cochran-Mantel-Haenszel test in rank a7.5 mg/dL for ETC-1002 and 26.0 mg/dL for placebo
[P 5 .2257]).
Twenty-one (62%) of the 34 patients in the ETC-1002
treatment arm who were not at LDL-C goal at baseline
achieved their LDL-C goal at week 8 or at the end of the
study (Fig. 5), whereas no placebo-treated patients reached
their LDL-C goal (95% CI for the difference between treat-
ment groups: 45%, 78%; P , .0001).
Safety
AEs were reported for 70% of ETC-1002–treated
patients and 79% of placebo-treated patients (Table 4).
Most AEs were mild or moderate in intensity and all
resolved by the end of the study. AEs considered to be
possibly or definitely related to study medication were
reported for 8 (22%) patients treated with ETC-1002 and
4 (21%) patients receiving placebo (Table 4). The only
events assessed as definitely related were tinnitus and
nausea in a patient treated with ETC-1002 and muscular
weakness in a placebo-treated patient. AEs resulting in
discontinuation were reported with similar frequency in
both treatment groups: 5 (14%) patients in the ETC-1002
group and 3 (16%) patients in the placebo group. Muscle-
related AEs caused all 3 discontinuations in the placebo
group and no discontinuations in the ETC-1002 group.
None of the events causing discontinuation were reported
for more than 1 patient in either treatment group. The
only serious AE reported was thyroid cancer in a patient
treated with ETC-1002. This was consistent with the pa-
tient’s medical history and was not considered related to
study drug. There were no deaths in the study.
Rates of muscle-related AEs characteristic of statin
intolerance were similar between the ETC-1002 and
placebo-treatment groups (27% and 32%, respectively)
(Table 4). Except for muscle spasms, which occurred in 5
ETC-1002–treated patients and 1 placebo-treated patient,eek 8 in lipoproprotein(a), free fatty acids, and high-sensitivity
Median (Q1, Q3) change, % P value‡t†
, 43.0) 0 (213.0, 20.0) .4304
, 33.0) 0 (216.0, 11.0) —
, 0.6) 11.5 (233.0, 37.0) .9531
, 0.6) 16.5 (214.0, 28.0) —
, 1.6) 242.0 (260.0, 216.0) .0022
, 4.9) 0 (210.0, 30.0) —
Q1, first (lower) quartile; Q3, third (upper) quartile.
ion-carried-forward procedure.
nalysis of covariance.
Figure 5 Patients achieving National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP-III) low-density
lipoprotein cholesterol (LDL-C) goal at the end of the study. Anal-
ysis included patients not at NCEP ATP-III goal at baseline
(n 5 34, ETC-1002; n 5 17, placebo). Missing values at week
8 were imputed using the last-observation-carried-forward proce-
dure. Asterisk, P , .0001 compared with placebo at week 8 (end
of study) based on the Fisher exact test.








Any treatment-emergent AEs 26 (70) 17 (79)
Treatment-related AEs, possible 7 (19) 3 (16)
Treatment-related AEs, definite 1 (3) 1 (5)
Serious AEs 1 (3)* 0
Most common AEs, nonmuscle related†
Upper respiratory tract infection 1 (3) 4 (21)
Arthralgia 1 (3) 2 (11)
Nausea 3 (8) 0
Urinary tract infection 3 (8) 0
Fatigue 2 (5) 1 (5)
Headache 2 (5) 1 (5)
Dizziness 2 (5) 0
Nasopharyngitis 2 (5) 0
Muscle-related treatment-emergent AEs‡
Any muscle-related AEs 10 (27) 6 (32)
Assessed as drug related 5 (14) 2 (11)
Resulting in discontinuation 0 3 (16)
Muscle fatigue 1 (3) 1 (5)
Muscle spasms 5 (14) 1 (5)
Muscle tightness 1 (3) 1 (5)
Muscular weakness 1 (3) 2 (11)
Musculoskeletal pain 0 1 (5)
Musculoskeletal stiffness 0 2 (11)
Myalgia 1 (3) 1 (5)
Pain in extremity 2 (5) 1 (5)
AE, adverse event.
*Thyroid cancer, not considered to be related to study drug.
†Occurring in$2 patients in either treatment group; excluding AEs
assessed in the post hoc analysis of muscle-related AEs.
‡Post hoc analysis of muscle-related AEs characteristic of statin
intolerance (all reported musculoskeletal and connective tissue disor-
ders except arthralgia, back pain, bursitis, joint stiffness, joint
swelling, plantar fasciitis, and spinal osteoarthritis).
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less common in the ETC-1002 group. Myalgia was reported
in 5% of patients receiving placebo and 3% of patients
treated with ETC-1002. Of the patients who developed a
muscle-related AE during the study, 6 patients in the
ETC-1002 group were on a statin at screening. No
placebo-treated patients who developed a muscle-related
AE during the study were on a statin at screening.
Few changes in laboratory parameters were observed.
From baseline to week 8, mean uric acid increased
1.2 6 0.7 mg/dL in the ETC-1002 group but decreased
0.08 6 0.9 mg/dL with placebo. Homocysteine increased
29.5 6 15.5% with ETC-1002 and decreased 3.4 6 9.4%
with placebo. Hemoglobin decreased 0.7 6 0.7 g/dL with
ETC-1002 and 0.1 6 0.6 g/dL with placebo. There was a
mean increase in CK of 12.0 6 46.7 U/L in the ETC-1002
group and 39.3 6 71.3 U/L in the placebo group. Glucose
decreased by 1.7 6 10.2 mg/dL with ETC-1002 and by
8.4 6 20.8 mg/dL with placebo (mean glucose values
at week 8 were similar between the groups: 93.6 mg/dL
with ETC-1002 at the final dose of 240 mg daily, and
94.0 mg/dL with placebo.) Overall, the magnitude of these
changes did not suggest any safety concerns. No patient
treated with ETC-1002 demonstrated an increase in liver
function tests $3 times ULN or CK $5 times ULN. There
were no clinically significant changes in physical findings,
vital signs, electrocardiograms, waist and ankle circumfer-
ence, or weight.Discussion
This early phase 2 study demonstrates that ETC-1002
reduced LDL-C 28.7% more than placebo in hyper-cholesterolemic patients with a history of statin-
associated muscle complaints. ETC-1002 also decreased
non–HDL-C, total cholesterol, apo B, and hsCRP more
than placebo. The dose of ETC-1002 was increased by
60 mg daily at 2-week intervals from 60 mg to 240 mg
daily. The aforementioned lipid parameters were decreased
at the first 2-week interval, but it is not clear whether
therapy continuing longer than 2 weeks would produce
more lipid reduction nor is it clear whether the 8-week
value represents the maximum lipid reduction. These
questions will be addressed in future studies, one of which
is a larger, 12-week, parallel-group study comparing ETC-
1002, 120 mg or 180 mg with ezetimibe 10 mg, alone or in
combination, in patients with or without statin intolerance
(NCT01941836).
ETC-1002 was administered for only 8 weeks in the
present study, and patients received the highest dose of
ETC-1002, 240 mg daily, for only 2 weeks. Nevertheless,
the frequency of TEAEs in patients treated with ETC-1002
Thompson et al ETC-1002 in patients with statin intolerance 303was similar to that noted in placebo-treated patients. There
were no substantial elevations in liver function or CK
measurements. Not surprisingly, given the population’s
history of statin-associated muscle complaints, the most
frequently reported AEs were musculoskeletal and connec-
tive tissue disorders in both the ETC-1002 and placebo
groups. Muscle-related AEs prompted discontinuation
of treatment in 3 (16%) placebo-treated patients but
no discontinuations occurred in patients treated with
ETC-1002.
This is the first study of ETC-1002 in patients with a
history of statin-associated muscle complaints. The lipid
results of this study are consistent with earlier trials in
which ETC-1002 in dosages up to 120 mg daily lowered
LDL-C by up to 27% in a general hypercholesterolemic
population treated for 12 weeks7 and by 43% in hypercho-
lesterolemic patients with diabetes treated for 4 weeks.8
Although ETC-1002 numerically increased triglyceride
levels in the present study, ETC-1002 numerically
decreased triglyceride levels in the previous phase 2
studies.7,8 Overall, ETC-1002 does not significantly change
triglyceride levels compared with placebo.
Ezetimibe is currently the most commonly prescri-
bed lipid-lowering medication for patients with statin-
associated muscle complaints.14 Results from prospective
studies of ezetimibe monotherapy in statin intolerant pa-
tients show reductions in LDL-C of 16%15 to 20%,16 which
are smaller reductions in LDL-C than those observed in the
present study with ETC-1002. The proportion of statin
intolerant patients achieving their 2004 NCEP ATP-III
goal for LDL-C with ezetimibe ranges from 9%16 to
29%.15 In the present study, 62% of patients treated with
ETC-1002 achieved their LDL-C goal at the end of study.
Ezetimibe is approved in Europe for use in patients with
statin myopathy, but has been associated with muscle-
related AEs in patients with statin-associated muscle
symptoms.15
Evolocumab, a monoclonal antibody to proprotein
convertase subtilisin/kexin type 9 (PCSK9) administered
subcutaneously, has been studied in statin intolerant
patients (Goal Achievement after Utilizing an anti-PCSK9
antibody in Statin Intolerant Subjects [GAUSS and
GAUSS-2]). Evolocumab reduced LDL-C by 51% to 56%
as monotherapy and by 63% when combined with ezeti-
mibe in statin intolerant patients.17,18 Myalgia was the most
common TEAE in both trials.17,18 Muscle-related AEs
occurred in 12% to 13% of patients treated with evolocu-
mab and 20% of those receiving evolocumab with ezeti-
mibe.17,18 Discontinuation rates for muscular AEs were
2% to 5% in patients treated with evolocumab, with or
without ezetimibe.17,18 These discontinuation rates for
muscle-related events are greater than those in the present
report of ETC-1002, but the duration of these studies
with evolocumab was 12 weeks, which is longer than the
present 8-week ETC-1002 trial.
Mipomersen is another cholesterol-lowering agent that
has been evaluated in patients with statin-associated musclecomplaints. In a phase 2, double-blind, randomized, con-
trolled trial involving 33 statin intolerant patients, once-
weekly mipomersen by subcutaneous injection lowered
LDL-C by 47%.19 However, persistent increases in ALT
$3 times ULN occurred in 33% of mipomersen-treated
patients, and hepatic steatosis was observed in 57% of
mipomersen-treated patients.19 In that 26-week trial by
Visser et al,19 43% of mipomersen-treated patients and
42% of placebo-treated patients experienced myalgia.
To date, other nonstatin lipid-lowering therapies,
including bile acid sequestrants, niacin, and fibrates, are
not well studied in patients with statin-associated muscle
complaints. Further, the lipid-lowering effects of these
agents are modest. In general populations with hyperlipid-
emia, bile acid sequestrants reduce LDL-C by 15% to
26%20 and niacin reduces LDL-C by 17% to 22%.21
Fibrates have minimal effects on LDL-C and are generally
reserved for reducing triglyceride levels.22
In the present study, ETC-1002 appeared well tolerated
vs placebo by patients with a history of statin-associated
muscle-related AEs who were treated for 8 weeks. Addi-
tional studies with longer treatment duration and direct
comparisons between ETC-1002 and other lipid-lowering
agents are required to better characterize the tolerability of
ETC-1002 in this patient population.
The definition of statin intolerance has evolved since this
study was undertaken. Although there is yet no universally
accepted definition, the criteria for statin intolerance used
in the present investigation is somewhat less rigorous than
the provisional definition recently proposed by the National
Lipid Association, which, among other things, specifies
intolerance to at least 2 statins and at specific dosage
intensities.23 Moreover, 27% of study participants were tak-
ing a statin at screening, before washout of lipid-lowering
drugs, and thus were not completely statin intolerant.
Further study of ETC-1002 in statin intolerant patients is
warranted.Conclusion
Clinically, the search for nonstatin lipid therapies
remains vital, and ETC-1002 compares favorably with
other nonstatin agents studied in statin intolerant patients.
Oral ETC-1002 produces significant reductions in LDL-C
compared with placebo in patients with prior statin-
associated myalgia, and most patients achieve their 2004
NCEP ATP-III LDL-C goal. There was no difference in
muscle complaints or safety parameters between the
ETC-1002 and placebo groups during the 8 weeks of the
study. ETC-1002 may provide an alternative to statins in
patients with statin-associated muscle complaints.Acknowledgments
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